An equity stake, not a takeover: partnering with Kirindo (2023)
Can independence and scale coexist?
The heart of this decision lies in deliberately avoiding full integration — choosing independence and complement — even as the majors bundled themselves into one- and two-trillion-yen alliances. Take a majority and you can consolidate the accounts, and your purchasing volume rises directly with it. Even so, President Sadakata held to a one-third stake and left the other side its autonomy. With a Kansai chain whose stores do not overlap his own, he would join forces on procurement and private-label development while each kept its independence. It was one answer to supplementing scale without being swallowed by the top alliances — a choice placed on the line of self-reliance running from Saizu’s day.
That said, the equity method carries limited influence, and it is harder to generate the procurement power of a full merger. The more independence you leave in place, the thinner the fruit that integration bears. Whether the gap to the $6.3B (¥1tn) sales target can be closed by this alliance and further M&A alone is not yet clear. In an industry where the majors assemble two-trillion-yen alliances, how is a mid-sized player to reconcile independence with scale? The equity-method partnership with Kirindo leaves that question open.
Revenue and net margin, FY2018–FY2026
Revenue in ¥ bn (bars) and net margin in % (line), for the years around the decision. Shaded columns are FY2023 onwards — after it was taken.
Source: securities reports
Read the full dossier in Japanese →
The Japanese edition carries the complete record of this decision — the situation that forced it, the options weighed, what actually followed, and the sources behind every claim.
Other key decisions at Sundrug
Yen amounts are converted at the average rate of each figure’s own year — not today’s rate; the revenue chart is shown in yen. Exchange rates & sources — the full ¥/US$ table →
Disclaimer
- This page is provided for general information only and is not investment advice, nor a recommendation to buy or sell any security.
- Figures are compiled independently and include our own estimates, approximations and machine-processed data; we make no warranty as to their accuracy or completeness.
- Sources are primarily each company’s securities reports and other public filings, but errors and omissions may remain.
- Any use of this information is at the reader’s own risk. Past performance does not indicate future results.
- Company names, logos and other marks belong to their respective owners.
Data API
Sundrug’s history, financials, executives and
shareholders are published as static JSON — no key, plain GET.
Full specification →
| Method | Endpoint | Returns |
|---|---|---|
| GET | /api/companies.json | All companies |
| GET | /api/9989/manifest.json | Resource index |
| GET | /api/9989/history.json | History overview |
| GET | /api/9989/timeline.json | Chronology |
| GET | /api/decisions.json | All management decisions (index) |
| GET | /api/9989/decisions.json | Management decisions (index) |
| GET | /api/9989/decisions/{slug}.json | One decision (full dossier) |
| GET | /api/9989/executives.json | Executives |
| GET | /api/9989/shareholders.json | Major shareholders |
| GET | /api/9989/financials.json | Financial statements |
| GET | /api/9989/financials-longterm.json | Long-term results |
| GET | /api/9989/segments.json | Business segments |
| GET | /api/9989/regions.json | Sales by region |
| GET | /api/9989/workforce.json | Workforce |